Clinical Trials match your criteria
-
PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA
-
Phase 2 study for Advanced PD-1 refractory melanoma
PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
-
Ph3 of MK6482 with Lenvatinib vs Cabozantinib for Advanced RCC
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy
-
Radiation Therapy on the First Visit: Virtual Radiation Treatment Planning for Palliative Cases
Radiation Therapy on the First Visit: Virtual Radiation Treatment Planning for Palliative Cases
-
PT GENIE
Home Physical Therapy Using an Avatar-based Digital Rehab Platform versus Traditional Office-based Physical Therapy After Reverse Shoulder Arthroplasty
-
Children’s Brain Tumor Tissue Consortium (CBTTC) Collection Protocol
Children’s Brain Tumor Tissue Consortium (CBTTC) Collection Protocol
-
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
ACNS1931 - A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
-
SurvivorLink: Scalability of an Electronic Personal Health Record
SurvivorLink: Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers
-
First-Line Treatment in Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
